allotrap

RN refers to Allotrap 07; small synthetic peptides derived from the alpha1 helix of the heavy chain of HLA class I proteins; inhibits human T cell responses in vitro; prolongs allograft survival in rats and mice

Also Known As:

Networked: 16 relevant articles (7 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Buelow, R: 5 articles (05/2003 - 02/2001)
2.	Buelow, Roland: 4 articles (09/2005 - 12/2003)
3.	Fong, Timothy: 3 articles (09/2005 - 04/2004)
4.	Iyer, Suhasini: 3 articles (09/2005 - 12/2003)
5.	Luo, Yi: 2 articles (06/2008 - 02/2005)
6.	Lazarov, Mirella: 2 articles (09/2005 - 08/2005)
7.	Valdez, Marybeth: 2 articles (09/2005 - 07/2004)
8.	Belmar, Nicole: 2 articles (02/2005 - 04/2004)
9.	Bourreille, A: 2 articles (05/2003 - 01/2003)
10.	Doubremelle, M: 2 articles (05/2003 - 01/2003)

Related Diseases

1.	Colitis 05/01/2003 - "The aims of this study were to investigate the anti-inflammatory properties of RDP58 ex vivo in human CD and in vivo in an experimental model colitis. " 01/01/2003 - "The aims of this study were to investigate the anti-inflammatory properties of RDP58 ex vivo in human CD and in vivo in an experimental model colitis. " 05/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. " 01/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. " 11/01/2002 - "RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis."
2.	Inflammation (Inflammations) 06/01/2008 - "In this study, we investigated whether RDP58 was effective as an intravesical agent for treating bladder autoimmune inflammation in a transgenic mouse model (URO-OVA mice). " 02/01/2001 - "The present study using Skh/hr hairless mouse skin model evaluated the in vivo effects of Allotrap 1258 on acute UVB-induced skin inflammation. " 06/01/2008 - "To determine whether the inhibition of bladder inflammation by RDP58 was due to the interference with effector T cells, we treated the cells with RDP58 in vitro. " 11/01/2002 - "RDP58 significantly reduced acute, chronic and total inflammation scores. " 05/01/2003 - "Inflammation was assessed following 7 days of oral therapy with RDP58 or vehicle alone. "
3.	Weight Loss (Weight Reduction) 05/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. " 01/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. "
4.	Cystitis 02/01/2005 - "In this study we evaluated the effects of intravesical RDP58 on an established model of cystitis. " 06/01/2008 - "Collectively, these results indicate that RDP58 is effective for treating T cell-mediated experimental autoimmune cystitis and may serve as a useful intravesical agent for the treatment of autoimmune-associated bladder inflammation such as IC." 06/01/2008 - "RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model." 08/01/2005 - "Re: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis." 02/01/2005 - "Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis."
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/01/2002 - "These findings indicate that RDP58 represents a new, orally available agent potentially useful in the treatment of inflammatory bowel disease."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Dextrans (Dextran)
3.	Sodium
4.	Fluorouracil (Carac)
5.	Tumor Necrosis Factor Inhibitors
6.	Irinotecan (Camptosar)
7.	Intercellular Signaling Peptides and Proteins (Growth Factors)
8.	Cytokines
9.	Protein Kinase C
10.	Carcinogens

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Cell Transplantation
4.	Drug Therapy (Chemotherapy)